Alpha 2u-globulin nephropathy: review of the cellular and molecular mechanisms involved and their implications for human risk assessment.
about
The p53 heterozygous knockout mouse as a model for chemical carcinogenesis in vascular tissuePotential health effects of gasoline and its constituents: A review of current literature (1990-1997) on toxicological dataRecommendations for the evaluation of complex genetic toxicity data sets when assessing carcinogenic risks to humans.Cell death and cell proliferation in the control of normal and neoplastic tissue growth.Historical control data from 13-week repeated toxicity studies in Crj:CD (SD) ratsDisposition and metabolism of cumene in F344 rats and B6C3F1 mice.Review of the carcinogenic potential of gasoline.Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findingsNovel insights into renal D-amino acid oxidase accumulation: propiverine changes DAAO localization and peroxisomal size in vivo.Promotion of liver and kidney carcinogenesis by ethyl tertiary-butyl ether (ETBE) in male Wistar rats.Safe human exposure limits for airborne linear siloxanes during spaceflight.A proposal to improve clarity and communication in the EU Classification process for chemicals for carcinogenicity and reproductive and developmental toxicity.Reassessment of MTBE cancer potency considering modes of action for MTBE and its metabolites.Binding of perfluorooctanoic acid to rat liver-form and kidney-form alpha2u-globulins.Editor's Highlight: Comparative Renal Safety Assessment of the Hepatitis B Drugs, Adefovir, Tenofovir, Telbivudine and Entecavir in Rats.Biotransformation and membrane transport in nephrotoxicity.Alternatives to the 2-species bioassay for the identification of potential human carcinogens.Concordance of Noncarcinogenic Endpoints in Rodent Chemical Bioassays.Scientific Opinion on the safety assessment of carvone, considering all sources of exposureA Comprehensive Toxicological Safety Assessment of an Extract of Olea Europaea L. Leaves (Bonolive™).Normal ranges and variability of novel urinary renal biomarkers in Sprague-Dawley Rats: comparison of constitutive values between males and females and across assay platforms.Meeting report: Urinary Pathology; sixth Research Triangle Park Rodent Pathology Course.Permitted Daily Exposure for Diisopropyl Ether as a Residual Solvent in Pharmaceuticals.What is the meaning of 'A compound is carcinogenic'?
P2860
Q28343851-2860C6B5-5FCD-4CAE-B3C2-63E693D3A63FQ28390027-E585773D-B2B5-4038-B775-D21F4821E817Q31171476-2F438F2D-00D1-4D31-9171-3E501FB1E54AQ33947654-23D4934C-DD39-4ADA-8056-725108DBF239Q34334105-16592215-0E47-4D24-8376-307A2CF25F72Q34702549-CBCB7A94-993F-4DA6-99C1-DD26CB379713Q34849300-C9E33912-3C12-442B-9773-0CF8CF7DD54CQ35603973-E96AF2E0-4FF3-47C8-96EA-49D41736B4E3Q35951912-08A1760C-4ED7-48BB-9C2E-53B2FC826862Q36157516-6D68984D-C746-49E4-9997-7562EBF738F4Q37455974-7442A445-15EF-49A1-B5A5-CA962C28A423Q38233637-AF12D35C-957C-40B8-987B-5B81D747DCD5Q38594604-7B3E0E6C-2C31-442A-868D-D4F41013C093Q39129370-8DACF979-F35C-4ADA-8756-3C7C0B0BE3C3Q40541312-589A6338-BE99-420B-AFFE-AC6A02107085Q41049463-56B500E7-BFFA-4EEE-B0B5-1EF675B132ADQ41137398-2C55CE05-F538-4650-A86E-93112E8346C4Q46793161-577BC117-1DC8-426B-BC31-5AD5DB4DB9CBQ47154855-097104B2-3B6B-452E-A451-B52AD258F66CQ50952424-FD3008C5-5BAF-4EA3-BAEC-876F9A896802Q51151105-BC01DA4C-E113-4C1E-BAB1-E87ADDC15D75Q53330942-0FB955C8-AA8A-4FF1-BF8E-BA3D98EC64CBQ55033296-F1CC19D2-C9BC-4990-8AF8-8524C2FE24D8Q55074220-E2DEC6BC-4C09-4C4A-AE05-4B0C739441FF
P2860
Alpha 2u-globulin nephropathy: review of the cellular and molecular mechanisms involved and their implications for human risk assessment.
description
1993 nî lūn-bûn
@nan
1993 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@ast
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@en
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@nl
type
label
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@ast
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@en
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@nl
prefLabel
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@ast
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@en
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@nl
P2860
P921
P356
P1476
Alpha 2u-globulin nephropathy: ...... ons for human risk assessment.
@en
P2093
Swenberg JA
P2860
P356
10.1289/EHP.93101S639
P478
101 Suppl 6
P577
1993-12-01T00:00:00Z